CD22low/Bcl-2high expression identifies poor response to inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia

Author:

Wintering Astrid1ORCID,Ishiyama Kenichi2ORCID,Tamaki Stanley3,Tamaki Courtney3,Fandel Joshua1,Ji Lingyun4,Wood Brent L.5ORCID,Shah Nirali N.6ORCID,Yuan Constance M.6ORCID,O’Brien Maureen M.7ORCID,Loh Mignon L.89,Diaz-Flores Ernesto1ORCID

Affiliation:

1. 1Department of Pediatrics, Benioff Children’s Hospital, and the Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA

2. 2Department of Microbiology and Immunology, University of California San Francisco, San Francisco, CA

3. 3Parnassus Flow Cytometry Core, University of California San Francisco, San Francisco, CA

4. 4Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA

5. 5Department of Pathology, Children’s Hospital Los Angeles, USC Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA

6. 6Center for Cancer Research, National Cancer Institute, Bethesda, MD

7. 7Division of Oncology, Cincinnati Children’s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH

8. 8Ben Towne Center for Childhood Cancer Research, Seattle Children’s Research Institute, University of Washington, Seattle, WA

9. 9Department of Pediatrics, Seattle Children’s Hospital, University of Washington, Seattle, WA

Publisher

American Society of Hematology

Subject

Hematology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3